Mesoblast Limited (MESO) vs Urogen Pharma (URGN)

Mesoblast Limited and Urogen Pharma are both Biotechnology companies. Mesoblast Limited and Urogen Pharma are of similar size ($2.0B and $2.0B). Urogen Pharma grew revenue faster over the last twelve months: 100.3% against −26.5%. Urogen Pharma has the higher net margin (−51.7% vs −1,091.7%) and the higher return on invested capital (0.00% vs 0.00%). Across the 16 metrics below, Urogen Pharma leads on 11 and Mesoblast Limited on 5.

Valuation

Metric MESO URGN Biotechnology median
P/E n/m n/m 7.88
P/S 156.77 11.04 11.47
P/B 2.05 n/m 2.52
Price to free cash flow n/m n/m 21.16
EV/EBITDA n/m n/m 0.74
EV/Sales 156.35 11.47 10.73
Earnings yield (7.41%) (4.79%) (28.84%)
Free cash flow yield (8.05%) (7.64%) (23.03%)

Profitability

Metric MESO URGN Biotechnology median
Gross margin (269.72%) 90.85% 65.16%
Operating margin (826.28%) (35.32%) 0.00%
Net margin (1,091.71%) (51.73%) 0.00%
Free cash flow margin 0.00% (84.32%) 0.00%
Return on equity 0.00% 86.49% (57.72%)
Return on assets 0.00% (42.33%) (49.22%)
Return on invested capital 0.00% 0.00% 0.00%

Growth

Metric MESO URGN Biotechnology median
Revenue growth (TTM) (26.54%) 100.27% 5.64%
EPS growth (last fiscal year) 48.24% (7.77%) —
Revenue growth, 5-year CAGR 74.39% 56.22% 8.40%
Net income growth, 5-year CAGR 0.00% 0.00% 0.00%

Health

Metric MESO URGN Biotechnology median
Debt to equity 0.22 (1.45) 0.00
Current ratio 1.58 3.80 4.73
Net debt to EBITDA (0.67) 0.00 0.96

Dividend

Metric MESO URGN Biotechnology median
Dividend yield — — 2.10%
Payout ratio 0.00 0.00 0.00

Size

Metric MESO URGN Biotechnology median
Market cap 2.01b 2.02b 162.10m

Compare with another peer

Any metric, up to five companies and an Excel export Powerpack